{"id":"ccrt-pf","safety":{"commonSideEffects":[{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hematologic toxicity"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Radiation dermatitis"}]},"_chembl":{"chemblId":"CHEMBL484929","moleculeType":"Small molecule","molecularWeight":"452.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a treatment protocol combining concurrent chemoradiotherapy (CCRT) with fluoropyrimidine chemotherapy (likely 5-FU or capecitabine). The concurrent approach aims to enhance local tumor control through radiation while systemic chemotherapy addresses micrometastatic disease. The fluoropyrimidine component acts as a radiosensitizer and provides cytotoxic activity.","oneSentence":"CCRT+ PF is a combination regimen pairing concurrent chemoradiotherapy with a fluoropyrimidine-based chemotherapy backbone.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:03.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced solid tumors (specific indication not clearly defined in available data)"}]},"trialDetails":[{"nctId":"NCT03840421","phase":"PHASE3","title":"GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-04-03","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases","enrollment":468},{"nctId":"NCT03321539","phase":"PHASE3","title":"Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2017-10-30","conditions":"Nasopharyngeal Carcinoma","enrollment":216},{"nctId":"NCT03306121","phase":"PHASE3","title":"TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2017-11-13","conditions":"Nasopharyngeal Carcinoma","enrollment":322},{"nctId":"NCT02940925","phase":"PHASE3","title":"TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-20","conditions":"Nasopharyngeal Carcinoma","enrollment":241},{"nctId":"NCT03883152","phase":"","title":"Eating Difficulties in HNC Patients - Influencing Factors and Short and Long Term Impacts on PF and Depression","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-06-27","conditions":"Head and Neck Cancer","enrollment":131},{"nctId":"NCT02812641","phase":"PHASE2","title":"Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2016-06","conditions":"Stage III Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT03574324","phase":"PHASE3","title":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-05-24","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adjuvant PF"],"phase":"phase_3","status":"active","brandName":"CCRT+ PF","genericName":"CCRT+ PF","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CCRT+ PF is a combination regimen pairing concurrent chemoradiotherapy with a fluoropyrimidine-based chemotherapy backbone. Used for Locally advanced solid tumors (specific indication not clearly defined in available data).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}